Prescription data related to the use of calcium channel blockers, ACE inhibitors and angiotensin II type 1 receptor antagonists (angiotensin receptor blockers) in combination identify savings opportunities

被引：0

作者：

Carugo S. ^{[1
]}

Rossetti G. ^{[1
]}

Merlino L. ^{[2
]}

Mancia G. ^{[3
]}

机构：

[1] ASP IMMeS e PAT, Istituto di Medicina Cardiovascolare, Centro Interuniversitario di Fisiologia Clinica e Ipertensione, Universit di Milano, Milan

[2] Operative Unit of Territorial Health Services, Milan, Region Lombardia

[3] Centro Interuniversitario di Fisiologia Clinica e Ipertensione, Universit di Milano Bicocca, Monza

来源：

High Blood Pressure & Cardiovascular Prevention | 2009年 / 16卷 / 1期

关键词：

ACE inhibitors; Angiotensin II antagonists; Calcium channel blockers; Combination therapy; Cost; Expenditure;

D O I：

10.2165/00151642-200916010-00004

中图分类号：

学科分类号：

摘要：

Background: It is now recognized that treating hypertension with combination therapy is required to achieve target blood pressure in the majority of patients. Objective: To investigate the use of ACE inhibitors, angiotensin II type 1 receptor antagonists (angiotensin receptor blockers [ARBs]) and calcium channel blockers (CCBs) within the Lombardia Region of Italy and to evaluate associated financial implications of the use of these drugs in free combinations. Methods: Prescription data in the Administrative National Health Service (NHS) Reimbursement Database of the Lombardia Region (2004-6) were analysed for ACE inhibitor, ARB and CCB use. Data included patient code, prescription date, drug class, product license number, number of packs dispensed and actual expenditure reimbursed by the NHS, and were used to calculate the mean daily cost of free combination antihypertensive treatments. Results: ACE inhibitors, ARBs or CCBs were prescribed at least once to 1.6 million patients (17% of Lombardia population) either as single therapy (51.5% of patients receiving these drugs) or in combination therapy (48.5%). mong patients who received these drugs, 22.5% received free combination therapy (primarily ACE inhibitor plus CCB or ARB plus CCB). The mean annual cost for these drugs was h342 million, representing 18% of the total annual pharmaceutical expenditure for the region. Free combinations accounted for 14.3% of treatment days, but 28.3% of annual expenditure for these drugs. Further analysis revealed that the mean expenditure for free combinations was 2.6-31.9% higher than the sum of their individual component costs (mean increase of 5.9% for the most commonly prescribed free combinations). Conclusions: Prescription of free combination of antihypertensive drugs is associated with additional financial burden to the NHS, which may be avoided by prescribing fixed combination therapy. © 2009 Adis Data Information BV.

引用

页码：21 / 26

页数：5

共 11 条

[1]

Zanchetti A., Hennig M., Baurecht H., Et al., Prevalence and incidence of the metabolic syndrome in the European Lacidipine Study on Atherosclerosis (ELSA) and its relation with carotid intima-media thickness, J Hypertens, 25, 12, pp. 2463-2470, (2007)

[2]

Leal J., Luengo-Fernandez R., Gray A., Et al., Economic burden of cardiovascular disease in the enlarged European Union, Eur Heart J, 27, 13, pp. 1610-1619, (2006)

[3]

OECD in figures, (2008)

[4]

Giampaoli S., Vescio M.F., Gaggioli A., Et al., Prevalence of arterial hypertension in the Italian population, Bollettino Epidemiologico, 15, (2002)

[5]

The use of medicinal products in Italy: 2006 report, (2007)

[6]

Jamerson K.A., The first hypertension trial comparing the effects of two fixed-dose combination therapy regimens on cardiovascular events: Avoiding Cardiovascular events through Combination therapy in Patients Living with Systolic Hypertension (ACCOMPLISH), J Clin Hypertens, 5, 4 SUPPL. 3, pp. 29-35, (2003)

[7]

Jamerson K.A., Bakris G.L., Wun C.C., Et al., Rationale and design of the Avoiding Cardiovascular events through Combination therapy in Patients Living with Systolic Hypertension (ACCOMPLISH) trial: The first randomized controlled trial to compare the clinical outcome effects of first-line combination therapies in hypertension, Am J Hypertens, 17, 9, pp. 793-801, (2004)

[8]

Jamerson K.A., on behalf of the ACCOMPLISH investigators. Avoiding Cardiovascular events in Combination therapy in Patients Living with Systolic Hypertension [abstract]. 57th Annual Scientific Session, (2008)

[9]

Neutel J.M., Smith D.H., Improving patient compliance: A major goal in the management of hypertension, J Clin Hypertens (Greenwich), 5, 2, pp. 127-132, (2003)

[10]

Dickson M., Plauschinat C.A., Compliance with antihypertensive therapy in the elderly: A comparison of fixed-dose combination amlodipine/benazepril versus component-based free-combination therapy, Am J Cardiovasc Drugs, 8, 1, pp. 45-50, (2008)

← 1 2 →